LIMINAL BIOSCIENCES INC (LMNL) Stock Fundamental Analysis

NASDAQ:LMNL • CA53272L2021

8.5 USD
+0.01 (+0.12%)
Last: Sep 25, 2023, 08:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

2

LMNL gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 521 industry peers in the Biotechnology industry. LMNL has a bad profitability rating. Also its financial health evaluation is rather negative. LMNL does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

3

1. Profitability

1.1 Basic Checks

  • In the past year LMNL was profitable.
  • In the past year LMNL has reported a negative cash flow from operations.
LMNL Yearly Net Income VS EBIT VS OCF VS FCFLMNL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 0 -50M -100M -150M -200M

1.2 Ratios

  • LMNL's Return On Assets of 1.46% is amongst the best of the industry. LMNL outperforms 93.73% of its industry peers.
  • With an excellent Return On Equity value of 2.16%, LMNL belongs to the best of the industry, outperforming 93.73% of the companies in the same industry.
Industry RankSector Rank
ROA 1.46%
ROE 2.16%
ROIC N/A
ROA(3y)-29.63%
ROA(5y)-80.67%
ROE(3y)-159.64%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
LMNL Yearly ROA, ROE, ROICLMNL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 0 200 -200 -400

1.3 Margins

  • The Profit Margin of LMNL (94.11%) is better than 99.67% of its industry peers.
  • The Operating Margin and Gross Margin are not available for LMNL so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) 94.11%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
LMNL Yearly Profit, Operating, Gross MarginsLMNL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 0 2K -2K -4K -6K -8K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. Health

2.1 Basic Checks

  • LMNL does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • LMNL has about the same amout of shares outstanding than it did 1 year ago.
  • Compared to 1 year ago, LMNL has an improved debt to assets ratio.
LMNL Yearly Shares OutstandingLMNL Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 5M 10M 15M 20M 25M
LMNL Yearly Total Debt VS Total AssetsLMNL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 50M 100M 150M 200M 250M

2.2 Solvency

  • LMNL has an Altman-Z score of -45.25. This is a bad value and indicates that LMNL is not financially healthy and even has some risk of bankruptcy.
  • LMNL has a Altman-Z score of -45.25. This is amonst the worse of the industry: LMNL underperforms 95.71% of its industry peers.
  • LMNL has a Debt/Equity ratio of 0.02. This is a healthy value indicating a solid balance between debt and equity.
  • LMNL has a Debt to Equity ratio (0.02) which is in line with its industry peers.
Industry RankSector Rank
Debt/Equity 0.02
Debt/FCF N/A
Altman-Z -45.25
ROIC/WACCN/A
WACC7.87%
LMNL Yearly LT Debt VS Equity VS FCFLMNL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 0 50M -50M 100M -100M

2.3 Liquidity

  • LMNL has a Current Ratio of 2.78. This indicates that LMNL is financially healthy and has no problem in meeting its short term obligations.
  • Looking at the Current ratio, with a value of 2.78, LMNL is doing worse than 74.75% of the companies in the same industry.
  • LMNL has a Quick Ratio of 2.78. This indicates that LMNL is financially healthy and has no problem in meeting its short term obligations.
  • LMNL's Quick ratio of 2.78 is on the low side compared to the rest of the industry. LMNL is outperformed by 72.94% of its industry peers.
Industry RankSector Rank
Current Ratio 2.78
Quick Ratio 2.78
LMNL Yearly Current Assets VS Current LiabilitesLMNL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 20M 40M 60M 80M 100M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

0

3. Growth

3.1 Past

  • The earnings per share for LMNL have decreased strongly by -99.10% in the last year.
  • Looking at the last year, LMNL shows a very negative growth in Revenue. The Revenue has decreased by -12.92% in the last year.
  • The Revenue for LMNL have been decreasing by -59.99% on average. This is quite bad
EPS 1Y (TTM)-99.1%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-53.93%
Revenue 1Y (TTM)-12.92%
Revenue growth 3Y-56.58%
Revenue growth 5Y-59.99%
Sales Q2Q%-28.66%

3.2 Future

  • LMNL is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -230.98% yearly.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-907.27%
EPS Next 2Y-230.98%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
LMNL Yearly Revenue VS EstimatesLMNL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 10M 20M 30M
LMNL Yearly EPS VS EstimatesLMNL Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 0 10 -10 -20 -30

More info and screens

Find the best growth stocksShow best growing peers

1

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings ratio is 77.27, which means the current valuation is very expensive for LMNL.
  • Based on the Price/Earnings ratio, LMNL is valued cheaper than 93.89% of the companies in the same industry.
  • The average S&P500 Price/Earnings ratio is at 27.05. LMNL is valued rather expensively when compared to this.
  • LMNL is expected to report negative earnings next year, which makes the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE 77.27
Fwd PE N/A
LMNL Price Earnings VS Forward Price EarningsLMNL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
LMNL Per share dataLMNL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5 -10

4.3 Compensation for Growth

  • LMNL's earnings are expected to decrease with -230.98% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-230.98%
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • LMNL does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

LIMINAL BIOSCIENCES INC

NASDAQ:LMNL (9/25/2023, 8:00:18 PM)

8.5

+0.01 (+0.12%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-08
Earnings (Next)11-07
Inst OwnersN/A
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap19.82M
Revenue(TTM)492.00K
Net Income(TTM)463.00K
Analysts43.33
Price Target7.65 (-10%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE 77.27
Fwd PE N/A
P/S 55.26
P/FCF N/A
P/OCF N/A
P/B 1.27
P/tB 1.59
EV/EBITDA N/A
EPS(TTM)0.11
EY1.29%
EPS(NY)-8.96
Fwd EYN/A
FCF(TTM)-11.29
FCFYN/A
OCF(TTM)-11.29
OCFYN/A
SpS0.15
BVpS6.71
TBVpS5.33
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA 1.46%
ROE 2.16%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) 94.11%
GM N/A
FCFM N/A
ROA(3y)-29.63%
ROA(5y)-80.67%
ROE(3y)-159.64%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.02
Health
Industry RankSector Rank
Debt/Equity 0.02
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 0.29%
Cap/Sales 0.61%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.78
Quick Ratio 2.78
Altman-Z -45.25
F-Score4
WACC7.87%
ROIC/WACCN/A
Cap/Depr(3y)12.21%
Cap/Depr(5y)35.07%
Cap/Sales(3y)46.16%
Cap/Sales(5y)49.99%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-99.1%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-53.93%
EPS Next Y-907.27%
EPS Next 2Y-230.98%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-12.92%
Revenue growth 3Y-56.58%
Revenue growth 5Y-59.99%
Sales Q2Q%-28.66%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y24.57%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y51.92%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y50.94%
OCF growth 3YN/A
OCF growth 5YN/A

LIMINAL BIOSCIENCES INC / LMNL FAQ

What is the ChartMill fundamental rating of LIMINAL BIOSCIENCES INC (LMNL) stock?

ChartMill assigns a fundamental rating of 2 / 10 to LMNL.


What is the valuation status for LMNL stock?

ChartMill assigns a valuation rating of 1 / 10 to LIMINAL BIOSCIENCES INC (LMNL). This can be considered as Overvalued.


Can you provide the profitability details for LIMINAL BIOSCIENCES INC?

LIMINAL BIOSCIENCES INC (LMNL) has a profitability rating of 3 / 10.


Can you provide the financial health for LMNL stock?

The financial health rating of LIMINAL BIOSCIENCES INC (LMNL) is 3 / 10.


What is the earnings growth outlook for LIMINAL BIOSCIENCES INC?

The Earnings per Share (EPS) of LIMINAL BIOSCIENCES INC (LMNL) is expected to decline by -907.27% in the next year.